BRISBANE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president and chief executive officer, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026 at 9:50 a.m. ET. A live webcast of the event can be accessed under the ‘Events & ...

Core Viewpoint - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with a focus on dry age-related macular degeneration (AMD) and geographic atrophy (GA), impacting nearly 10 million people globally [1][8] Company Overview - Annexon is a biopharmaceutical company specializing in immunotherapies aimed at neuroinflammatory diseases [1][8] - The company is developing vonaprument, a C1q inhibitor designed to be the first targeted vision-preserving therapy for GA [6][8] Event Announcement - Annexon will host a key opinion leader (KOL) event in New York on March 18, 2026, featuring presentations on dry AMD and GA [1][2] - The event will include a live Q&A session following the formal presentations [2] Expert Contributions - Dr. Eleonora Lad and Dr. Charles C. Wykoff will present at the event, focusing on the unmet needs in GA treatment and the mechanism of disease [5] - Dr. Lad's research includes the role of neuroinflammation in AMD and the development of innovative diagnostic approaches [3] - Dr. Wykoff has extensive experience in clinical trials and research related to retinal diseases [4] Product Development - Vonaprument is a clinical-stage investigational therapy that selectively inhibits C1q, aiming to protect retinal function [6] - The drug has received Fast Track designation from the FDA and Priority Medicine designation from the European Medicines Agency [6] Clinical Trial Information - The Phase 3 ARCHER II trial has enrolled over 630 patients with advanced dry AMD and GA, with a primary endpoint of preventing a ≥15-letter loss in best corrected visual acuity [7] - Topline data from the trial is expected in the second half of 2026 [7]

Core Insights - Systemic complement-mediated diseases are relatively rare, but complement overactivation significantly impacts a broader range of hard-to-treat diseases, affecting quality of life [1] Group 1 - Complement overactivation plays a significant role in various diseases that are challenging to treat [1] - These diseases often have serious implications for patients' quality of life [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Company Overview - Annexon is a biotech company based in Bayera, focusing on immunotherapy to treat neuroinflammatory diseases, with a mission to deliver transformative therapies for patients [2] - The company has two major registrational stage programs that target a market opportunity exceeding $10 billion and aim to treat over 10 million patients annually [2] Product Pipeline - The lead program is focused on dry Age-related Macular Degeneration (AMD) with geographic atrophy, which is a significant cause of blindness, and the drug candidate, vonaprument (ANX007), has shown substantial vision protection in affected patients [3] - The second drug candidate, tanruprubart, is aimed at treating Guillain-Barre syndrome [3]

Summary of Annexon Conference Call Company Overview - **Company**: Annexon - **Industry**: Biotechnology, specifically focusing on immunotherapy for neuroinflammatory diseases - **Mission**: Deliver game-changing immunotherapy for patients suffering from devastating neuroinflammatory diseases [2][3] Key Programs and Market Opportunities ANX007 for Geographic Atrophy (GA) - **Market Opportunity**: Addressing a market potential of over $10 billion annually, with the ability to treat more than 10 million patients [3][4] - **Phase 3 Data**: Expected release in the second half of 2026, with a focus on vision preservation in patients with GA [4][22] - **Patient Demographics**: Average age of patients in studies is 79 years, with significant vision loss impacting independence [11] - **Efficacy**: Demonstrated protection of 50%-60% of photoreceptor cells, leading to a 73% reduction in the risk of vision loss over 12 months [15][18][19] - **Safety Profile**: Low incidence of adverse events compared to other therapies, with no significant conversion to wet AMD [25] ANX005 for Guillain-Barré Syndrome (GBS) - **Market Opportunity**: Affects 150,000 people worldwide, with a healthcare cost exceeding $7 billion annually in the U.S. [27][28] - **Efficacy**: 90% of treated patients showed improvement by week one, with significant reductions in inflammatory biomarkers [30][31] - **Patient Outcomes**: Patients returned to walking 31 days sooner and were off ventilators 28 days earlier compared to placebo [32] - **Regulatory Status**: Filed for European approval, with plans to submit to the FDA later in 2026 [34] ANX1502 for Autoimmune Conditions - **Development Status**: First oral small molecule candidate targeting autoimmune conditions, with proof of concept data expected in 2026 [5][35] - **Challenges**: Initial formulation issues related to emesis and food effects have been addressed with enteric-coated formulations [46][48] Competitive Advantage - **Scientific Approach**: Focus on targeting C1q in the classical pathway, differentiating from first-generation therapies targeting downstream pathways [6][24] - **Experienced Leadership**: The team has over 100 years of combined biotech experience, enhancing the company's ability to navigate challenges [9] Regulatory and Commercial Strategy - **Regulatory Designations**: Prime designation in the EU and fast track designation in the U.S. for ANX007 [22][40] - **Market Preparation**: Actively preparing for market entry with effective medical education and pre-commercial activities [5] Conclusion - **Transformational Year**: 2026 is positioned as a pivotal year for Annexon, with significant milestones expected in both GA and GBS programs [34] - **Investment Opportunity**: The company presents a unique value proposition for investors, particularly with its late-stage programs and differentiated therapeutic approaches [9][23]

Core Insights - Annexon, Inc. is advancing targeted immunotherapies for neuroinflammatory diseases, with a focus on two lead programs: tanruprubart for Guillain-Barré Syndrome (GBS) and vonaprument for Geographic Atrophy (GA) [1][2] Strategic Priorities and Milestones - 2026 is identified as a pivotal year for Annexon, with plans for the first potential approval of tanruprubart in GBS and pivotal Phase 3 data for vonaprument in GA [2][3] - The Marketing Authorization Application (MAA) for tanruprubart has been filed in Europe, with a U.S. Biologics License Application (BLA) submission planned for 2026 [2][4] - The ongoing Phase 3 ARCHER II trial for vonaprument has completed enrollment of 659 patients ahead of schedule, aiming to establish it as the first treatment approved for vision protection in dry AMD with GA [5] Product Development and Clinical Trials - Tanruprubart is positioned as a fast-acting therapy for GBS, with a comprehensive data package demonstrating rapid impact on neuroinflammation and improved patient outcomes compared to standard treatments [5][6] - Vonaprument has shown significant protection of photoreceptors in the retina, with expectations for topline Phase 3 data in the second half of 2026 [5][6] - The proof-of-concept trial for ANX1502, an oral C1 inhibitor for autoimmune diseases, is anticipated to provide updates in 2026 [6][9] Financial Position - Annexon maintains a strong financial position, which is expected to fund operations into late 2027, well past anticipated key milestones [1][2]

Core Insights - Annexon, Inc. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart, a potential first targeted fast-acting therapy for Guillain-Barré syndrome (GBS) [1][2] - The company plans to submit a Biologics License Application (BLA) to the FDA in 2026, with data from the ongoing FORWARD trial [1][3] Company Overview - Annexon is focused on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally [1][7] - The company aims to provide meaningful functional benefits and alter the course of diseases by stopping classical complement-driven neuroinflammation [7] Product Details - Tanruprubart is a first-in-class antibody designed to block classical complement-driven inflammation, showing rapid effects in stopping early nerve damage in GBS patients [2][4] - The therapy has received Orphan Drug designations from both the FDA and EMA, indicating a recognized need for improved treatments [2][5] Clinical Data - The MAA submission included comprehensive data demonstrating that tanruprubart allows patients to recover faster and more completely compared to existing treatments [3][4] - The ongoing FORWARD study aims to support a broad label for both pediatric and adult patients, expanding the use of tanruprubart across different geographies [3][4] Disease Context - GBS is a rare neuromuscular emergency affecting over 150,000 people annually worldwide, with no approved treatments in the U.S. [2][6] - The disease leads to significant morbidity and has a multi-billion-dollar annual economic cost to the U.S. healthcare system [6]

Core Insights - Annexon, Inc. is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million people globally [1][3]. Company Overview - Annexon is advancing a next-generation platform of targeted immunotherapies aimed at addressing serious neuroinflammatory diseases [3]. - The company's scientific approach centers on C1q, a molecule that initiates a potent inflammatory pathway, which can lead to tissue damage when misdirected [3]. - Annexon's therapies are designed to halt classical complement-driven neuroinflammation at its source, aiming to provide significant functional benefits and alter disease progression [3]. - The mission of Annexon is to deliver transformative therapies to patients, enabling them to lead their best lives [3]. Upcoming Events - Douglas Love, the president and CEO of Annexon, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, at 11:15 a.m. PST [1]. - A live webcast of the presentation will be available on the company's Investors page, with a replay archived for 30 days post-event [2].

Core Insights - Annexon Inc. (NASDAQ:ANNX) is highlighted as a promising multibagger penny stock, with Clear Street initiating coverage with a Buy rating and a price target of $17, driven by advancements in complement inhibitors for inflammation-related diseases [1][2]. Group 1: Pipeline Development - The lead asset vonaprument for geographic atrophy (GA) has shown positive results in Phase 2 trials, with pivotal data expected in the second half of next year, which could enhance clinical confidence and market access [2]. - Another key product, Tanruprubart, targeting Guillain-Barré syndrome (GBS), has also yielded positive data in pivotal studies, with a European regulatory submission planned for early next year [2]. - The oral complement inhibitor ANX1502 is in early clinical development and is anticipated to be a significant treatment option in a category currently dominated by injected or infused therapies [3]. Group 2: Analyst Ratings and Price Targets - Wells Fargo has reiterated an overweight rating on Annexon, raising the price target from $14 to $27, reflecting confidence in the positive outcomes of Vonaprument's Phase 3 GA trial expected in the second half of 2026 [4]. Group 3: Company Overview - Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation medicines targeting the classical complement pathway (C1q) to treat severe autoimmune, neurodegenerative, and ophthalmic diseases, including GBS and GA [5].